Bio-Rad Laboratories, Inc.
BIO
NYSE
Health Technology
Medical Specialties
305.96
USD
+4.26
+1.41%
Geschlossen: 07-22 20:00 (UTC+0)
305.96
USD
+1.34
+0.44%
Vorbörslich: 07-23 08:26 (UTC+0)

BIO Wichtige Statistiken

Hoch
307.10
Öffnen
301.00
Volumen
275.06K
Niedrig
298.74
Vorheriger Schlusskurs
301.70
Handelswert
84.03M
52W-Hoch
343.12
Rel. Volumen
0.897
Amplitude (%)
2.77%
52W-Tief
236.73
Umsatzrate
1.27%
Marktkapitalisierung
8.18B
KGV (TTM)
50.37
KGV (Jährlich)
10.978
KBV
1.2
KUV
3.16
Gewinn je Aktie (EPS)
6.075
Dividende (TTM)
0
Dividendenrendite
0.00%
Ausstehende Aktien
21.70M
Währung
USD

BIO Preis-Performance

7 Tag
30 Tag
90 Tag
180 Tag
Seit Jahresbeginn
1 Jahr
BIO Moneyflow-Verteilung
BIO Tägliches Leerverkaufsvolumen
BIO Short-Interest-Historie
As of 2026-07-23, the Bio-Rad Laboratories, Inc. (BIO) stock price today is 305.96. Based on this price, the company has a market capitalization of $8.18B, with a P/E ratio of 50.37. On 2026-07-23, BIO traded between 298.74 and 307.10. Today’s stock price is 2.42% above the daily low and 0.37% below the daily high, placing BIO nahe dem oberen Ende von its most recent trading range. Trading volume currently stands at 275.06K, compared with an average daily volume of 306.76K. This suggests that trading activity is ungefähr im Einklang mit dem üblichen Niveau than usual. Over the past year, Bio-Rad Laboratories, Inc. shares have traded between 236.73 and 343.12. At today’s price, BIO is 29.24% above its 52-week low and 10.83% below its 52-week high.
Firmenname
Bio-Rad Laboratories, Inc.
Sektor
Health Technology
Branche
Medical Specialties
Börsen
NYSE
Anzahl der Beschäftigten
7,450
Losgröße
40
Offizielle Website
Währung
USD
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.

BIO FAQ